Compositions and methods for antigen targeting to CD180

1. A composition, comprising:

(a) an antibody that selectively binds CD180 or an antigen binding fragment thereof; and

(b) a heterologous polypeptide antigen covalently attached to the antibody that selectively binds CD180 or the antigen binding fragment thereof, wherein the heterologous polypeptide antigen is selected from the group consisting of a pathogen-specific polypeptide antigen and a disease-related polypeptide antigen.

2. The composition of claim 1 , wherein the heterologous antigen comprises a pathogen-specific polypeptide antigen, wherein the pathogen-specific polypeptide antigen comprises a polypeptide antigen of a pathogen selected from the group consisting of hepatitis virus, human papillomavirus, herpes simplex viruses, cytomegalovirus, Epstein-Barr virus, influenza virus, parainfluenza virus, enterovirus, measles virus, mumps virus, polio virus, rabies virus, human immunodeficiency virus, respiratory syncytial virus, Rotavirus, rubella virus, varicella zoster virus, Ebola virus, cytomegalovirus, Marburg virus, norovirus, variola virus, West Nile virus, yellow fever virus, dengue virus, tick-borne encephalitis virus, Japanese encephalitis virus, human immunodeficiency virus (HIV), Bacillus anthracis, Bordetalla pertusis, Chlamydia trachomatis, Clostridium tetani, Clastridium difficile, Corynebacterium diptheriae, Coxiella burnetii, Escherichia coli, Haemophilus influenza, Helicobacter pylori, Leishmania donovani, L. tropica and L. braziliensis, Mycobacterium tuberculosis, Mycobacterium leprae, Neisseria meningitis, Plasmodium falciparum, P. ovale, P. malariae and P. vivax, Pseudomonas aeruginosa, Salmonella typhi, Schistosoma hematobium, S. mansoni, Streptococcus pneumoniae (group A and B), Staphylococcus aureus, Toxoplasma gondii, Trypanosoma brucei, T cruzi and Vibrio cholera.

3. The composition of claim 1 , wherein the heterologous polypeptide antigen comprises a disease-related polypeptide antigen.

4. The composition of claim 3 , wherein the disease-related polypeptide antigen comprises an antigen expressed on a tumor cell surface.

5. The composition of claim 4 , wherein the antigen expressed on a tumor cell surface is selected from the group consisting of p53, alphafetoprotein, carcinoembryonic antigen, CA-125, human epidermal growth factor receptor-2, MUC-1, NY-ESO-1, epithelial tumor antigen, tyrosinase, and melanoma-associated antigen gene-1.

6. The composition of claim 3 , wherein the heterologous polypeptide antigen comprises beta amyloid.

7. The composition of claim 1 , wherein the antibody or antibody fragment that binds CD180 is a CD180 monoclonal antibody or an antigen binding fragment thereof.

8. The composition of claim 7 , wherein the CD180 monoclonal antibody or an antigen binding fragment thereof comprises a human or animal CD180 binding domain linked to an immunoglobulin constant region (Fc) domain that has impaired binding to human or animal Fc receptor FcγRIlb and/or to human or animal complement proteins.

9. The composition of claim 1 , wherein the heterologous polypeptide antigen comprises a hepatitis B virus antigen.

10. The composition of claim 9 , wherein the antibody or antibody fragment that binds CD180 is a CD180 monoclonal antibody or an antigen binding fragment thereof.

11. The composition of claim 10 , wherein the CD180 monoclonal antibody or an antigen binding fragment thereof comprises a human or animal CD180 binding domain linked to an immunoglobulin constant region (Fc) domain that has impaired binding to human or animal Fc receptor FcγRIIb and/or to human or animal complement proteins.

12. The composition of claim 1 , wherein the composition further comprises an adjuvant.

13. The composition of claim 12 , wherein the adjuvant is selected from the group consisting of a toll-like receptor 7 (TLR7) agonist and a toll-like receptor 9 (TLR9) agonist.

14. The composition of claim 9 , wherein the composition further comprises an adjuvant.

15. The composition of claim 14 , wherein the adjuvant is selected from the group consisting of a toll-like receptor 7 (TLR7) agonist and a toll-like receptor 9 (TLR9) agonist.

16. An isolated nucleic acid encoding the composition of claim 1 .

17. A nucleic acid vector comprising the isolated nucleic acid of claim 16 .

18. A recombinant host cell comprising the nucleic acid vector of claim 17 .

19. A pharmaceutical composition, comprising:

(a) the composition of claim 1 ; and

(b) a pharmaceutically acceptable carrier.